Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular m...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

StockBodega Sep. 9 at 10:28 AM

$DERM $FBIO $FBIOP https://finance.yahoo.com/healthcare/articles/journey-medical-corporation-participate-september-200500610.html

0 · Reply

makrodimutross Sep. 2 at 1:30 AM

$FBIO $FBIOP Millennium Management LLC reporting a (new?) 5% position in the company with 1,778,561 shares. Wow.

3 · Reply

Chaka1647 Aug. 31 at 4:18 PM

Another ~20 cents today (eventually) from $FBIOP

0 · Reply

makrodimutross Aug. 26 at 4:06 PM

$FBIOP Arrears keep growing at 0.1953 per share per month. Sept balance will be $5.27... Which means we are currently trading at 40% discount to liquidation preference. DERM is almost breakeven. Royalties for UNLOXCYT and ZYCUBO will continue to grow. Some people in whom I highly trust think 2028 for reinstatement. I am personally in the 2027 camp, which means I believe they will clear the arrears by the end of this fiscal year in order to access the baby shelf and continued equity financing via S-3 for FY2027. Going into November this year, FBIOP arrears will be about $8 per share. This will cost the company just over 27m to clear the arrears and access S-3 financing. If they decide to go into November of NEXT year, FBIOP arrears will be around 35m going into FY2028. And FBIO commons will trade sideways due to this overhang. Like many have said, this is not a matter of "if", but a matter of "when"

2 · Reply

Hedgehog13 Aug. 23 at 4:40 AM

$FBIOP Less and less selling by disappointed short-term traders. Fresh bids. Expecting a comeback to $22 or higher soon, while we wait for the announcement.

1 · Reply

Kconn52 Aug. 18 at 12:32 PM

$FBIOP For those of you who are wondering about the potential timing of restoration of the dividend on this security, here are the relevant dates. Even if a material default is subsequently cured or waived, the issuer remains ineligible to use Form S-3 during the period between the date of the default and the filing of the audited financial statements for that fiscal year. So, FBIO would have to cure the default before 12-31-2026 to be eligible, after the filing of the FY2026 audited financials indicating that the default had been cured, to use an ATM during 2027.

1 · Reply

1000kv Aug. 15 at 4:26 PM

$FBIOP I asked Claude to look through the 10 q and compare to my earlier model of cash flow. One note that was called out was in the notes to the financial statements and may impact the timing yet of the reinstatement. "In July 2026, Cyprium declared a cash dividend of approximately $118.6 million, of which approximately $95.4 million was payable to Fortress." I feel a little better on timing, but I think an announcement by the end of q-3 reporting is getting important to make the timeline for reinstatement of ATM next year. Just an opinion, please do your own DD. If anyone has a different take on the way this works, please update with your thoughts.

1 · Reply

FinSUN Aug. 14 at 10:44 PM

$FBIOP $FBIO debt holders first, then insiders... and insiders want OUT... the whole Fortress capital and business shenanigan is all about sell to a third party... damn, it's the entire principle business model... When they sell.. and they will sell, they will convert, get the majority of the company, vote YES to an acquisition that is convenient to them and retire... by the time that happens they will the interest due to preferred will obliterate any current commons' OS number... Maybe selling to someone that will repeat the game... rinse and repeat. All you can do is trade. The ultimate game of this play is NOT shareholderd value, not the way you would expect from a public company. If you don't get this you will waste years and grow bitter. Understanding the capital structure, the governance and the incentives is 90% of the game in stocks like this.. the other 10% is knowing how to trade a manipulated and structurally drugged small cap, like many others.

1 · Reply

FinSUN Aug. 14 at 10:35 PM

$FBIOP still waiting on those dividends ? 😂

0 · Reply

makrodimutross Aug. 14 at 5:35 PM

$FBIO $FBIOP One of these EITHER OR conditions were met at the time of the PRV Sale. (Positive net assets) The other condition (Net profits) is on track to be met by next year. "Fiduciary duty to common shareholders" is a joke. Was it "fiduciary duty" to pay down the Oaktree Loan? Resoundingly, YES. Likewise, it would also be considered "fiduciary duty" to pay the arrears owed to preferred stockholders. They simply don't care, and refuse to communicate with earnings calls, or even reply to emails from concerned investors. The only acceptable answer to this would be if they are negotiating with potential partners, and in possession of significant definitive material non-public information.

1 · Reply

Market Cap	N/A
Revenue (ttm)	84.51M
Net Income (ttm)	-60.64M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	304
Avg Vol	18,892
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	79%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A